Related references
Note: Only part of the references are listed.Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia
Khaled M. Musallam et al.
BLOOD (2013)
Genetic modifiers of sickle cell disease
Martin H. Steinberg et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia
Khaled M. Musallam et al.
BLOOD (2012)
The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia
Swee Lay Thein
BLOOD REVIEWS (2012)
The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells
Ariel Amaru Calzada et al.
EXPERIMENTAL HEMATOLOGY (2012)
Update on fetal hemoglobin gene regulation in hemoglobinopathies
Daniel E. Bauer et al.
CURRENT OPINION IN PEDIATRICS (2011)
HDAC Inhibition in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
Jelena Vojinovic et al.
MOLECULAR MEDICINE (2011)
Pharmacokinetics, Safety and Inducible Cytokine Responses during a Phase 1 Trial of the Oral Histone Deacetylase Inhibitor ITF2357 (Givinostat)
Antonio Furlan et al.
MOLECULAR MEDICINE (2011)
Targeted Therapeutic Strategies for Fetal Hemoglobin Induction
Vijay G. Sankaran
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2011)
Fetal globin gene inducers: novel agents and new potential
Susan P. Perrine et al.
COOLEY'S ANEMIA: NINTH SYMPOSIUM (2010)
Pharmacologic Induction of Fetal Hemoglobin Production
George Atweh et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2010)
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease
James E. Bradner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies
Ugo Testa
ANNALS OF HEMATOLOGY (2009)
Erythroid differentiation and maturation from peripheral CD34+ cells in liquid culture:: Cellular and molecular characterization
Luisa Ronzoni et al.
BLOOD CELLS MOLECULES AND DISEASES (2008)
Genetic modifiers of the β-haemoglobinopathies
Swee Lay Thein
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34(+) cells
Laure A. Moutouh-de Parseval et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Hydroxyurea for the treatment of sickle cell anemia
Orah S. Platt
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells
J. Golay et al.
LEUKEMIA (2007)
The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on
Piotr Chomczynski et al.
NATURE PROTOCOLS (2006)
Mortality in sickle cell patients on hydroxyurea therapy
SM Bakanay et al.
BLOOD (2005)
Induction of human γ globin gene expression by histone deacetylase inhibitors
H Cao et al.
BLOOD (2004)
Effect of hydroxyurea on mortality. and morbidity in adult sickle cell anemia - Risks and benefits up to 9 years of treatment
MH Steinberg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin
O Witt et al.
BLOOD (2003)
Oral isobutyramide therapy in patients with thalassemia intermedia: Results of a phase II open study
MD Cappellini et al.
BLOOD CELLS MOLECULES AND DISEASES (2000)
Share Paper
